MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which Reneo shareholders will only own approximately 31% of the combined company.
If you remain a Reneo shareholder and have concerns about the transaction, you may contact our firm at the following link to discuss your legal rights at no charge :
https://wohlfruchter.com/cases/reneo-pharmaceuticals/
Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com .
Why is there an investigation?
On May 13, 2024, Reneo announced that it had agreed to merge with OnKure in a stock-for-stock transaction under which Reneo shareholders will only own approximately 31% of the combined company.
“We are investigating whether the Reneo Board of Directors acted in the best interests of Reneo shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the percentage of the combined company allocated to Reneo shareholders is fair, and whether all material information regarding the transaction has been fully disclosed.”
About Wohl & Fruchter
Wohl & Fruchter LLP has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com , to learn more about our Firm, or contact one of our partners.
Contact:
Wohl & Fruchter LLP
Joshua E. Fruchter
Toll Free 866.833.6245
alerts@wohlfruchter.com
www.wohlfruchter.com